Roger Preston
Adjunct Assistant Professor, Biochemistry


Roger Preston obtained his BSc. (Hons) in Molecular Biology from University of Aberdeen, and then completed a MSc. in Bioengineering at the University of Strathclyde. He was awarded his PhD by Imperial College London in 2004. Upon returning to Ireland, his research was funded by a Health Research Board Research Fellowship. He is currently funded by a prestigious Science Foundation Ireland Starting Investigator Research Grant. He is the recipient of research prizes from Haematology Association of Ireland (Scholar Award), Novo Nordisk ('Access-To-Insight' Research Award) and Bayer HealthCare (Hemophilia Program, Early Investigator Award).

Publications and Further Research Outputs

Peer-Reviewed Publications

Gleeson EM, O'Donnell JS, Hams E, Ni Ainle F, Kenny BA, Fallon PG, Preston RJ. , Activated Factor X signaling via protease-activated receptor 2 suppresses pro-inflammatory cytokine prodution from LPS-stimulated myeloid cells., Haematologica, 99, (1), 2014, p185 - 193 Journal Article, 2014 TARA - Full Text DOI

Preston RJ, Rawley O, Gleeson EM, O'Donnell JS, Elucidating the role of carbohydrate determinants in regulating hemostasis: insights and opportunities., Blood, 121, (19), 2013, p3801 - 3810 Journal Article, 2013

McGrath RT, van den Biggelaar M, Byrne B, O'Sullivan JM, Rawley O, O'Kennedy R, Voorberg J, Preston RJ, O'Donnell JS. , Altered glycosylation of platelet-derived von Willebrand factor confers resistance to ADAMTS13 proteolysis. , Blood, 122, (25), 2013, p4107 - 4110 Journal Article, 2013

Gleeson EM, O'Donnell JS, Preston RJ, The endothelial cell protein C receptor: cell surface conductor of cytoprotective coagulation factor signaling., Cellular and molecular life sciences : CMLS, 69, (5), 2012, p717-26 Journal Article, 2012

Ní Ainle F, O'Donnell JS, Johnson JA, Brown L, Gleeson EM, Smith OP, Preston RJ, Activated protein C N-linked glycans modulate cytoprotective signaling function on endothelial cells., The Journal of biological chemistry, 286, (2), 2011, p1323-30 Journal Article, 2011 DOI

McGrath RT, McKinnon TA, Byrne B, O' Kennedy R, Terraube V, McRae E, Preston RJ, Laffan MA, and O'Donnell JS., Expression of terminal 2-6 linked sialic acid on von Willebrand factor specifically enhances proteolysis by ADAMTS13 Blood, Blood, 115, (13), 2010, p2666-2673 Journal Article, 2010 DOI

Bridges DJ, Bunn J, van Mourik JA, Grau G, Preston RJ, Molyneux M, Combes V, O'Donnell JS, de Laat B, Craig A., Rapid activation of endothelial cells enables P. falciparum adhesion to platelet decorated von Willebrand factor strings, Blood, 115, (7), 2010, p1472-1474 Journal Article, 2010 DOI

Larkin, D, de Laat, B, Jenkins, PV, Bunn, J, Craig, AG, Terraube, V, Preston, RJ, Donkor, C, Grau, GE, van Mourik, JA, O'Donnell, JS, Severe Plasmodium falciparum malaria is associated with circulating ultra-large von Willebrand multimers and ADAMTS13 inhibition., PLoS Pathogens, 5, (3), 2009, p1 - 8 Journal Article, 2009 TARA - Full Text DOI

Preston, RJ, Tran, S, Johnson, JA, Ainle, FN, Harmon, S, White, B, Smith, OP, Jenkins, PV, Dahlbäck, B, O'Donnell, JS, Platelet factor 4 impairs the anticoagulant activity of activated protein C., The Journal of Biological Chemistry, 284, (9), 2009, p5869 - 5875 Journal Article, 2009 TARA - Full Text DOI

Cunningham, MS, Preston, RJ, O'Donnell, JS, Does antithrombotic therapy improve survival in cancer patients?, Blood Reviews, 23, (3), 2009, p129 - 135 Journal Article, 2009 DOI

Harmon, S, Preston, RJ, Ainle, FN, Johnson, JA, Cunningham, MS, Smith, OP, White, B, O'Donnell, JS, Dissociation of activated protein C functions by elimination of protein S cofactor enhancement., The Journal of Biological Chemistry, 283, (45), 2008, p30531 - 30539 Journal Article, 2008 TARA - Full Text DOI

Preston, RJ, Morse, C, Murden, SL, Brady, SK, O'Donnell, JS, Mumford, AD, The protein C omega-loop substitution Asn2Ile is associated with reduced protein C anticoagulant activity., British Journal of Haematology, 144, (6), 2008, p946 - 953 Journal Article, 2008 DOI

Hochart, H, Jenkins, PV, Preston, RJ, Smith, OP, White, B, O'Donnell, J, Concentration-dependent roles for heparin in modifying lipopolysaccharide-induced activation of mononuclear cells in whole blood., Thrombosis and Haemostasis, 99, (3), 2008, p570 - 575 Journal Article, 2008 DOI

Zanardelli, S, Crawley, JT, Chion, CK, Lam, JK, Preston, RJ, Lane, DA, ADAMTS13 substrate recognition of von Willebrand factor A2 domain., The Journal of Biological Chemistry, 281, (3), 2006, p1555 - 1563 Journal Article, 2006 DOI TARA - Full Text

Persson, KE, Stenflo, J, Linse, S, Stenberg, Y, Preston, RJ, Lane, DA, Rezende, SM, Binding of calcium to anticoagulant protein S: role of the fourth EGF module., Biochemistry, 45, (35), 2006, p10682 - 10689 Journal Article, 2006 DOI

Mollica, L, Preston, RJ, Chion, AC, Lees, SJ, Collins, P, Lewis, S, Lane, DA, Autoantibodies to thrombin directed against both of its cryptic exosites., British Journal of Haematology, 132, (4), 2006, p487 - 493 Journal Article, 2006 DOI

Preston, RJ, Ajzner, E, Razzari, C, Karageorgi, S, Dua, S, Dahlbäck, B, Lane, DA, Multifunctional specificity of the protein C/activated protein C Gla domain., The Journal of Biological Chemistry, 281, (39), 2006, p28850 - 28857 Journal Article, 2006 DOI

Preston, RJ, Villegas-Mendez, A, Sun, YH, Hermida, J, Simioni, P, Philippou, H, Dahlbäck, B, Lane, DA, Selective modulation of protein C affinity for EPCR and phospholipids by Gla domain mutation., The FEBS Journal, 272, (1), 2005, p97 - 108 Journal Article, 2005 DOI

Biguzzi, E, Razzari, C, Lane, DA, Castaman, G, Cappellari, A, Bucciarelli, P, Fontana, G, Margaglione, M, D'Andrea, G, Simmonds, RE, Rezende, SM, Preston, RJ, Prisco, D, Faioni, EM, Molecular diversity and thrombotic risk in protein S deficiency: the PROSIT study., Human Mutation, 25, (3), 2005, p259 - 269 Journal Article, 2005 DOI

Preston RJ, Lane DA., APC stripped bare, Blood, 104, 2004, p1595-1596 Journal Article, 2004 URL

Kevane B, Donnelly JC, D'Alton M, Cooley SM, Preston RJ, Ní Áinle F., Risk factors for pregnancy-associated venous thromboembolism: a review. , Journal of Perinatal Medicine Journal Article,

Research Expertise


Administration of recombinant versions of endogenous plasma proteins is a common therapeutic approach to hematological and inflammatory disorders, but can be expensive, immunogenic and associated with undesirable side-effects. Dr. Preston's research seeks to address these deficiencies by generating enhanced recombinant therapeutics through innovative bioengineering of existing plasma proteins. To date, his group has developed a number of unique recombinant mutant plasma proteins possessing enhanced properties with significant therapeutic potential. These novel drug candidates have been created via manipulation of enzymatic activity, protein interaction, substrate recognition and post-translational modification. The ultimate aim of this approach is to develop new treatment approaches for adult and paediatric inflammatory, haemostatic and malignant diseases. Dr. Preston's research group is currently funded by a combination of charitable, governmental and industrial sources. These include the Paediatric Research in Translational Immunology Program at the National Children's Research Centre, a Science Foundation Ireland Starting Investigator Award and a Bayer Hemophilia Program Early Career Investigator Award.


Blood Diseases; Hemophilia; Thrombosis


Awards and Honours

Bayer HealthCare Hemophilia Program - Early Career Investigator Award 2013

Health Research Board Research Fellowship 2006-2009

Science Foundation Ireland Starting Investigator 2009

Haematology Association of Ireland Scholar Award 2010

Novo Nordisk Access-To-Insight Award 2010


International Society of Thrombosis and Haemostasis 2007

Haematology Association of Ireland 2009 – 2010